peripheral arterial disease/diarrhea

Cilostazol is a unique antiplatelet agent that has been commercially available for over two decades. As a phosphodiesterase III inhibitor, it reversibly inhibits platelet aggregation yet also possesses vasodilatory and antiproliferative properties. It has been widely studied in a variety of disease

Clopidogrel is an oral antiplatelet agent used in the treatment of coronary artery disease, peripheral vascular disease and cerebrovascular disease. Gastrointestinal symptoms including nausea, diarrhea and constipation are the common side effects of this drug. Serious side effects like intracranial

This article is the sixth in the series of clinical updates on nursing home care. The topics covered are management of hypertension, antidepressant medications in people with dementia, peripheral arterial disease, probiotics in prevention, and treatment of Clostridium difficile-associated diarrhea,

Acute mesenteric ischemia presents a clinical challenge due to its subtle presentation and high mortality rate, which can mimic a variety of other conditions. Acute mesenteric ischemia requires a high index of suspicion, especially in those with comorbidities and risk factors such as hypertension,

BACKGROUND Dependent erythema or rubor is an erythematous discoloration of the limbs, most commonly associated with peripheral artery disease. We present a case of florid dependent erythema, associated with additional autonomic symptoms. METHODS Examination and full workup of a 16-year-old healthy

Ischemic stroke, myocardial infarction and peripheral arterial disease are different clinical manifestations commonly due to the same underlying disease, i.e. atherosclerosis with subsequent thrombosis/embolism (atherothrombosis). Many clinical trials of secondary prevention after stroke or TIA have

OBJECTIVE To ascertain the role of cardiovascular risk factors, cardiovascular diseases, standard treatments and other diseases in the development of ischemic colitis (IC). METHODS A retrospective, case-control study was designed, using matched data and covering 161 incident cases of IC who required

OBJECTIVE To review the pharmacology and clinical utility of cilostazol, an antiplatelet and vasodilator agent approved for the management of intermittent claudication. METHODS Primary literature on cilostazol was identified from a comprehensive MEDLINE literature search (1980-February 2000).

METHODS A 48-year-old diabetic with multiple co-morbidities presented with generalized micro- and macroangiopathy including peripheral artery disease stage IV with necroses in several digits of both feet. He was admitted to the department of surgery for the insertion of femoropopliteal